Preview

The Scientific Notes of the Pavlov University

Advanced search

Epidemiology and results of the first line therapy for HIV-related Hodgkin lymphoma

https://doi.org/10.24884/1607-4181-2022-29-3-65-73

Abstract

Introduction. The risk of developing Hodgkin lymphoma (HL) with HIV infection is higher than in the general population, and the course of the disease itself is more aggressive. Currently, there is no unified approach to the treatment of HIV-related HL, and data on its epidemiology in the Russian Federation are limited.

The objective was to study epidemiological characteristics, the used therapeutic tactics and the results of treatment for HIV-related HL.

Methods and materials. The multicenter retrospective study included 46 patients with HIV- related HL treated in 9 centers of the Russian Federation. Descriptive statistics methods were used, the analysis of overall survival (OS) and progression-free survival (PFS) was performed using the Kaplan–Meier method.

Results. HIV-related HL is more often represented by an advanced stage, B-symptoms, and extranodal lesions. The ABVD regimen was used as the first-line therapy in 60 % for HIV-related HL. The overall response to therapy was 81.6 %, and the 2-year OS and PFS were 85 % and 49 %, respectively. Factors that worsened OS were CD4+˂266 cells/mcL and general somatic status ECOG≥2. 

About the Authors

A. M. Chekalov
Pavlov University
Russian Federation

Hematologist of the Oncological Department № 2 (Chemotherapy and BMT) of the Clinic of Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation, Postgraduate Student of the Department of
Hematology, Transfusiology, Transplantology with the Course of Pediatric Oncology of the Faculty of Postgraduate Education named after Prof. B. V. Afanasyev, 

Saint Petersburg



M. O. Popova
Pavlov University

Cand. of Sci. (Med.), Associate Professor of the Department of Hematology, Transfusiology and Transplantology with the Course of Pediatric Oncology of the Faculty of Postgraduate Education named after Prof. B. V. Afanasyev, Hematologist of Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation, 

Saint Petersburg



I. V. Tsygankov
Pavlov University

Oncologist of the Oncological Department № 2 (Chemotherapy and BMT) of the Clinic of Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation, 

Saint Petersburg



Yu. A. Rogacheva
Pavlov University

Hematologist of the Department of Bone Marrow Transplantation for Adults of the Clinic of Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Postgraduate Student of the Department of Hematology, Transfusiology, Transplantology with the Course of Pediatric Oncology of the Faculty of Postgraduate Education named after Prof. B. V. Afanasyev, 

Saint Petersburg



N. P. Volkov
Pavlov University

Hematologist of the Department of Bone Marrow Transplantation for Adults of the Clinic of Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology,

Saint Petersburg



K. V. Lepik
Pavlov University

Cand. of Sci. (Med.), Head of the Oncological Department № 2 (Chemotherapy and BMT) of the Clinic of Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, 

Saint Petersburg



M. V. Demchenkova
Irkutsk Regional Cancer Center

Head of Chemotherapeutic Department № 4 – Antitumor Drug Therapy with Bone Marrow Transplantation Unit, 

Irkutsk



T. V. Schneider
Leningrad Regional Clinical Hospital

Head of the Oncohematological Department № 1 with the Use of Chemotherapy, 

Saint Petersburg



Yu. V. Kopeikina
Leningrad Regional Clinical Hospital

Hematologist of Oncohematological Department № 1 with the Use of Chemotherapy, 

Saint Petersburg



N. V. Medvedeva
Municipal clinical hospital № 31

Cand. of Sci. (Med.), Deputy Chief Physician for Treatment,

Saint Petersburg



I. S. Zyuzgin
National Medical Research Center of Oncology named after N.N. Petrov

Cand. of Sci. (Med.), Head of the Department of Hematology and Bone Marrow Transplantation, 

Saint Petersburg



E. S. Pavlyuchenko
North-Western State Medical University named after I. I. Mechnikov

Head of the Department of Hematology and Chemotherapy of the Clinic named after E. E. Eichwald, 

Saint Petersburg



A. N. Levanov
Saratov State Medical University

Assistant of the Department of Occupational Pathology, Hematology and Clinical Pharmacology,

Saratov



A. A. Myasnikov
V. A. Baranov Republican Hospital

Cand. of Sci. (Med.), Head of the Hematological Department, 

Petrozavodsk, Republic of Karelia



E. V. Kariagina
City Hospital № 15

Head of the Department of Oncohematology, Chemotherapy and Bone Marrow Transplantation № 11, 

Saint Petersburg



N. B. Mikhailova
Pavlov University

Cand. of Sci. (Med.), Head of the Department of Clinical Oncology of the Clinic of Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Associate Professor of the Department of Hematology, Transfusiology, Transplantology with the Course of Pediatric Oncology of the Faculty of Postgraduate Education named after Prof. B. V. Afanasyev,

Saint Petersburg



V. V. Baykov
Pavlov University

Dr. of Sci. (Med.), Associate Professor of the Department of Pathological Anatomy, Head of the Laboratory of Pathomorphology of Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, 

Saint Petersburg



A. D. Kulagin
Pavlov University

Dr. of Sci. (Med.), Head of the Department of Hematology, Transfusiology, Transplantology with the Course of Pediatric Oncology of the Faculty of Postgraduate Education named after Prof. B. V. Afanasyev, Director of the Clinic of Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology,

Saint Petersburg



References

1. Silverberg M. J., Lau B., Achenbach C. J., Jing Y., Althoff K. N., D’Souza G., Engels E. A., Hessol N. A., Brooks J. T., BurchellA. N., Gill M.J., GoedertJ.J., Hogg R., Horberg M. A., Kirk G. D., Kitahata M. M., Korthuis P. T., Mathews W. C., MayorA., Dubrow R. Cumulative Incidence of CancerAmong PersonsWith HIV in NorthAmerica:ACohort Study //Annals of Internal Medicine. 2015;163(7):507– 518. Doi: https://doi.org/10.7326/M14-2768.

2. Powles T., Robinson D., Stebbing J., Shamash J., Nelson M., Gazzard B., Mandelia S., Møller H., Bower M. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection // Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2009;27(6):884–890. Doi: https://doi.org/10.1200/JCO.2008.19.6626.

3. Biggar R. J., Jaffe E. S., Goedert J. J., Chaturvedi A., Pfeiffer R., Engels E. A. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS // Blood. 2006; 108(12): 3786–3791. Doi: https://doi.org/10.1182/BLOOD2006-05-024109.

4. Carroll V., Garzino-Demo A. (2015). HIV-associated lymphoma in the era of combination antiretroviral therapy: shifting the immunological landscape // Pathogens and Disease. 2015;73(7). Doi: https://doi.org/10.1093/FEMSPD/FTV044.

5. GoedertJ.J., Bower M. (2012). Impact of highly effective antiretroviral therapy on the risk for Hodgkin lymphoma among people with human immunodeficiency virus infection // Current Opinion in Oncology. 2012;24(5):531–536. Doi: https://doi.org/10.1097/CCO.0B013E3283560697.

6. Lanoy E., Rosenberg P. S., Fily F., Lascaux A. S., Martinez V., Partisani M., Poizot-Martin I., Rouveix E., Engels E. A., Costagliola D., Goedert, J. J. HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy // Blood. 2011;118(1): 44–49. Doi: https://doi.org/10.1182/BLOOD-2011-02-339275.

7. Gotti D., Danesi M., Calabresi A., Ferraresi A., Albini L., Donato F., Castelli F., Scalzini A., Quiros-Roldan E. (2013). Clinical characteristics, incidence, and risk factors of HIV-related Hodgkin lymphoma in the era of combination antiretroviral therapy // AIDS Patient Care and STDs. 2013;27(5):259–265. Doi: https://doi.org/10.1089/APC. 2012.0424.

8. Tirelli U., Errante D., Dolcetti R., Gloghini A., Serraino D., Vaccher E., Franceschi S., Boiocchi M., Carbone A. (1995). Hodgkin’s disease and human immunodeficiency virusinfection: clinicopathologic and virologic features of 114 patients from the Italian Cooperative Group on AIDS and Tumors//Journal ofClinical Oncology: OfficialJournal ofthe American Society of Clinical Oncology. 1995;13(7):1758– 1767. Doi: https://doi.org/10.1200/JCO.1995.13.7.1758.

9. Hjalgrim H.,Askling J., Rostgaard K., Hamilton-Dutoit S., Frisch M., Zhang J.-S., Madsen M., Rosdahl N., Konradsen H. B., Storm H. H., Melbye M. (2003). Characteristics of Hodgkin’s lymphoma after infectious mononucleosis // The New England Journal of Medicine. 2003;349(14):1324–1332. Doi: https://doi.org/10.1056/NEJMOA023141.

10. Carbone A., Gloghini A., Caruso A., de Paoli P., Dolcetti R. (2017). The impact of EBV and HIV infection on the microenvironmental niche underlying Hodgkin lymphoma pathogenesis // International Journal of Cancer. 2017;140(6):1233–1245. Doi: https://doi.org/10.1002/IJC. 30473.

11. HanX.,JemalA.,HullandE.,SimardE.P.,Nastoupil L., Ward E., Flowers C. R. (2017). HIV infection and survival of lymphoma patients in the era of highly active antiretroviral therapy // Cancer Epidemiology Biomarkers and Prevention. 2017;26(3):303–311. Doi: https://doi.org/10.1158/1055-9965. EPI-16-0595/69206/AM/HIV-INFECTION-AND-SURVIVAL-OF-LYMPHOMA-PATIENTS-IN.

12. Besson C., Lancar R., Prevot S., Brice P., Meyohas M. C., Marchou B., Gabarre J., Bonnet F., Goujard C., Lambotte O., Boue F., Mounier N., Partisani M., Raffi F., Costello R. T., Ghesquieres H., Hendel-Chavez H., Genin M., Marchand L., Costagliola D. Characteristics and Outcome of HIV Associated Classical Hodgkin’s Lymphoma Among 68 Patients Included in the French ANRS CO16 Lymphovir Cohort Study // Blood. 2014;124(21): 2954. Doi: https://doi.org/10.1182/BLOOD.V124.21.2954.2954.

13. Cingolani A., Lepri A. C., Teofili L., Galli L., Mazzotta V., Baldin G. M., Hohaus S., Bandera A., Alba L., Galizzi N., Castagna A., D’arminio Monforte A., Antinori A. (2017). Survival and predictors of death in people with HIV-associated lymphoma compared to those with a diagnosis of lymphoma in general population // PloS One. 2017;12(10). Doi: https://doi.org/10.1371/JOURNAL.PONE.0186549.

14. Gopal S., Patel M. R., Yanik E. L., Cole S. R., Achenbach C. J., Napravnik S., Burkholder G. A., Reid E. G., Rodriguez B., Deeks S. G., Mayer K. H., Moore R. D., Kitahata M. M., Eron J. J., Richards K. L. Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era // Journal of the National Cancer Institute. 2013;105(16):1221–1229. Doi: https://doi.org/10.1093/JNCI/DJT158.

15. Hentrich M.,Berger M.,WyenC., SiehlJ.,Rockstroh J. K., Müller M., Fätkenheuer G., Seidel E., Nickelsen M., Wolf T., Rieke A., Schürmann D., Schmidmaier R., Planker M.,AltJ., Mosthaf F., EngertA.,Arasteh K., Hoffmann C. Stage-adapted treatment of HIV-associated hodgkin lymphoma: Results of a prospective multicenter study // Journal of Clinical Oncology. 2012;30(33):4117–4123. Doi: https://doi.org/10.1200/JCO.2012.41.8137.

16. Uldrick T. S., Little R. F. How I treat classical Hodgkin lymphoma in patientsinfected with human immunodeficiency virus // Blood. 2015;125(8):1226–1235. Doi: https://doi.org/10.1182/BLOOD-2014-08-551598.

17. Deborah Freedman-Cass N., Schonfeld R., Reid E., Suneja G., Al-Rohil R., Ambinder R. F., Ard K., Baiocchi R., CarchmanE.,Christensen S.,CryslerO.V.,GoyalG.,Gupta N., HenryD.H.,JonesA.,KloppA.,LaCasceA. S.,Lin C.,LurieR. H.Continue NCCN Guidelines Panel Disclosures HIV+Aging ResearchProject-PalmSpringsCancerinPeoplewithHIV. 2022.

18. Moiseev I. S.,Alekseev S. M., Mikhailova N. B. et al. Results of the Russian Multi-Center Cooperative Prospective-Retrospective Observational Program for Hodgkin’s Lymphoma Treatment RNWOHGHD1 // Clinical oncohematology. 2021;14(4):455–465. (In Russ.).

19. Rubinstein P. G., Moore P. C., Rudek M. A., Henry D. H., Ramos J. C., Ratner L., Reid E., Sharon E., Noy A. Brentuximab vedotin with AVD shows safety, in the absence of strong CYP3A4 inhibitors, in newly diagnosed HIV-associated Hodgkin lymphoma // AIDS (London, England). 2018;32(5):605–611. Doi: https://doi.org/10.1097/QAD. 0000000000001729.

20. Pivnik A. V., Vukovich A. M., Kremneva N. V. et al. Hodgkin’s Lymphoma in HIV-Infected Patients // Clinical oncohematology. 2021;14(1):63–68. (In Russ). Doi: 10. 21320/2500-2139-2021-14-1-63-68.

21. Caroline Besson, Remi Lancar, Sophie Prevot, Pauline Brice, Marie-Caroline Meyohas, Bruno Marchou, Jean Gabarre, Fabrice Bonnet, Cécile Goujard, Olivier Lambotte, François Boué, Nicolas Mounier, Marialuisa Partisani, Francois Raffi, Régis Costello, Houria Hendel-Chavez, Michele Algarte-Genin, SelmaTrabelsi, Lucie Marchand, Martine Raphael, Yassine Taoufik, Dominique Costagliola, High Risk Features Contrast With Favorable Outcomes in HIV-associated Hodgkin Lymphoma in the Modern cART Era, ANRS CO16 LYMPHOVIR Cohort // Clinical Infectious Diseases. 2015;61(Is. 9):1469–1475. Doi: https://doi.org/10.1093/cid/civ627.

22. Horner M. J. R. L., Krapcho M., Neyman N. et al. SEER Cancer Statistics Review, 1975–2006, National Cancer Institute. November 2008, SEER data submission, posted to the SEER web site, Bethesda, Md, USA, 2009. Available at: http://seer.cancer.gov/csr/1975_2006/.

23. Jacobson C. A., Abramson J. S. HIV-Associated Hodgkin’s Lymphoma: Prognosis and Therapy in the Era of cART //Advancesin Hematology. 2012. Doi: https://doi.org/10.1155/2012/507257.

24. Berenguer Juan, Miralles Pilar, Ribera José María, Rubio Rafael, Valencia Eulalia, Mahillo Beatriz, Pintado Vicente, Palacios Rosario, Montes María Luisa, Téllez María Jesús, La Cruz José, Torre-Cisneros Julián, Rodríguez-Arrondo Francisco, Sepúlveda María Antonia, Gutiérrez Félix, Peralta Galo, Boix Vicente on Behalf of the GESIDA Register of Systemic AIDS-Related Lymphomas Characteristics and Outcome of AIDS-Related Hodgkin Lymphoma Before and After the Introduction of Highly Active Antiretroviral Therapy // JAIDS Journal of Acquired Immune Deficiency Syndromes. 2008; 47(Is. 4):422–428. Doi: 10.1097/QAI.0b013e31815e722b.


Supplementary files

Review

For citations:


Chekalov A.M., Popova M.O., Tsygankov I.V., Rogacheva Yu.A., Volkov N.P., Lepik K.V., Demchenkova M.V., Schneider T.V., Kopeikina Yu.V., Medvedeva N.V., Zyuzgin I.S., Pavlyuchenko E.S., Levanov A.N., Myasnikov A.A., Kariagina E.V., Mikhailova N.B., Baykov V.V., Kulagin A.D. Epidemiology and results of the first line therapy for HIV-related Hodgkin lymphoma. The Scientific Notes of the Pavlov University. 2022;29(3):65-73. (In Russ.) https://doi.org/10.24884/1607-4181-2022-29-3-65-73

Views: 481


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1607-4181 (Print)
ISSN 2541-8807 (Online)